Company Overview
Snapshot
Founded in October 1996, OrSense operates with 11–50 employees. The company has raised a total of $44.4 million across 6 funding rounds from 3 investors. In May 2019, OrSense received FDA market clearance for its NBM200 noninvasive hemoglobin system, marking a significant regulatory achievement.
Business overview
OrSense is a medical device company specializing in the development and commercialization of noninvasive monitoring technologies. The company's core product, based on its patented SpectOLight technology and occlusion spectroscopy, utilizes a finger-attached, ring-shaped sensor probe to measure blood parameters such as hemoglobin, oxygen saturation, and glucose. This technology generates a strong optical signal by temporarily occluding blood flow, enabling sensitive and specific blood analysis. OrSense serves the health tech and life sciences sectors, providing solutions for continuous and spot measurements in medical applications.
Strategic signal
In May 2019, OrSense secured FDA market clearance for its NBM200 noninvasive hemoglobin system, making it the first noninvasive hemoglobin system approved for use in blood donation centers. This regulatory approval is a strong validation of OrSense's technology and opens up significant market opportunities within the blood donation and transfusion industry, signaling potential for broader adoption of its noninvasive monitoring solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is OrSense's core technology?
- OrSense's core technology is SpectOLight, which uses occlusion spectroscopy with a non-invasive optical measurement platform and a finger-attached, ring-shaped sensor probe to measure blood parameters.
- When did OrSense receive FDA clearance for its NBM200 system?
- In May 2019, OrSense received FDA market clearance for its NBM200, the first noninvasive hemoglobin system cleared for use in blood donation centers.
- Which markets has OrSense expanded into?
- In October 2014, OrSense delivered its first systems in Mexico, indicating market expansion into Latin America.
- Which investors participated in OrSense's May 2011 funding round?
- In May 2011, OrSense received funding from investors including Lewis Trust Group.
- What is the primary application of OrSense's technology?
- OrSense develops and commercializes noninvasive monitoring technologies for continuous and spot measurements of hemoglobin, oxygen saturation, glucose, and other blood parameters.